VKH
ARGS

Virtu KCG Holdings’s Argos Therapeutics, Inc. ARGS Stock Holding History

Virtu KCG Holdings’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,354
Closed -$57K – 3969
2017
Q1 		$57K Buy
+6,354
New +$402K ﹤0.01% 2813
2016
Q3 		– Sell
-1,328
Closed -$163K – 3859
2016
Q2 		$163K Buy
+1,328
New +$177K ﹤0.01% 2396

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Virtu KCG Holdings's ARGS Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 6,354 shares — an estimated $57K sold.

Virtu KCG Holdings first reported a position in ARGS in Q2 2016 and held it in 2 quarters. The position peaked at $163K in Q2 2016. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 6,354 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $57K.
  • Virtu KCG Holdings first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • Virtu KCG Holdings's Argos Therapeutics, Inc. position peaked at $163K in Q2 2016.
  • 34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.